Alcaniz

Researchers are collecting detailed information about patients with venous thromboembolism (VTE), which includes blood clots in veins such as deep-vein thrombosis and pulmonary embolism. The project aims to improve doctors' understanding of VTE, especially in patients often excluded from clinical trials, like pregnant women, elderly individuals, cancer patients, and those with other complex health issues. The goal is to reduce deaths, clot recurrence, bleeding problems, and artery-related events by sharing this knowledge widely. The study involves gathering extensive data on each patient's health status, treatments, and outcomes during the first three months of therapy. This registry is available online to help doctors quickly find information on patients with similar medical profiles and make informed decisions about managing high-risk individuals. There are no specific interventions being tested; instead, the focus is on collecting real-world patient data. Participants provide informed consent and are followed for at least three years to monitor for new clot events and complications. Researchers track recurrences of VTE, bleeding episodes, and deaths, aiming to create tools that predict which patients are most at risk for problems. This ongoing data collection supports improving care and guiding treatment decisions for diverse patient groups over time.

The study focuses on patients with splenomegaly or those who have undergone splenectomy without a clear diagnosis, as well as patients with thrombocytopenia. Researchers aim to improve diagnosis sensitivity for Gaucher disease (GD) and Acid Sphingomyelinase Deficiency (ASMD) among these patients, especially in those with monoclonal gammopathies of undetermined significance (MGUS) or multiple myeloma (MM). Previous research suggests increased frequency of MGUS and MM in GD and ASMD patients, but many cases of splenomegaly remain unexplained despite standard evaluations. The study involves the use of usual clinical diagnostic procedures alongside collecting blood samples for a dry drop test (DBS) to measure enzymatic and genetic activity related to GD and ASMD. Analysis of specific markers LisoGl1 and LisoSM will also be conducted. The investigation seeks to identify the prevalence of these diseases in the patient population over a 36-month period. Participants will undergo clinical evaluation, blood testing, and enzymatic/genetic assessments to help identify GD and ASMD. Researchers will monitor the prevalence of these diseases and related conditions throughout the study. The study includes adult patients aged 18 to 99 years, and those who participate will provide consent for assessments and follow-up. Safety and diagnostic results will be observed during the entire study duration.